Life Science REIT Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Simon Farnsworth

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	2.2yrs
Gemiddelde ambtstermijn bestuur	3.1yrs

Recente managementupdates

Recent updates

CEO

Simon Farnsworth (57 yo)

no data

Tenure

Mr. Simon Farnsworth serves as Managing Director of Ironstone Asset Management Limited, Investment Adviser of Life Science REIT plc. He served as a Senior Director and Head of Value-Added Investments at CB...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Sally Forsyth	Independent Non-Executive Director	2.5yrs	UK£40.00k	0.0058% £ 7.8k
Simon Farnsworth	Managing Director of Ironstone Asset Management Limited	no data	geen gegevens	geen gegevens
David Lewis	Director of Operations & Finance of Ironstone Asset Management Limited	no data	geen gegevens	geen gegevens
Joanna Waddingham	Head of Investor Relations & Corporate Affairs of Ironstone Asset Management Limited	1.8yrs	geen gegevens	geen gegevens
Stephanie Adams	Legal Counsel of Ironstone Asset Management Limited	no data	geen gegevens	geen gegevens
Ian Harris	Director of Asset Management of Ironstone Asset Management Limited	no data	geen gegevens	geen gegevens
Pippa Stacey	Head of ESG & Consultant of Ironstone Asset Management Limited	no data	geen gegevens	geen gegevens
Tamara Deering	Head of Financial Planning & Reporting of Ironstone Asset Management Limited	no data	geen gegevens	geen gegevens
Daniel Williams	Corporate & Development Financial Controller - Ironstone Asset Management Limited	2.2yrs	geen gegevens	geen gegevens

2.2yrs

Gemiddelde duur

Ervaren management: Het managementteam van LABS wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Sally Forsyth	Independent Non-Executive Director	3.1yrs	UK£40.00k	0.0058% £ 7.8k
Richard Howell	Senior Independent Non-Executive Director	2.5yrs	UK£45.00k	0.0086% £ 11.5k
Claire Boyle	Independent Non-Executive Chairman of the Board	3.1yrs	UK£55.00k	0.0086% £ 11.5k
Michael Taylor	Independent Non-Executive Director	3.1yrs	UK£40.00k	0.0057% £ 7.7k

3.1yrs

Gemiddelde duur

60.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van LABS wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.1 jaar).

Life Science REIT Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Life Science REIT plc, Annual General Meeting, May 23, 2024

High number of new and inexperienced directors

Life Science REIT plc Approves Election of Directors

Life Science Reit plc Announces Change of Role of Richard Howell from Non-Executive Director to Senior Independent Director and Appointment as Chair of the Audit and Risk Committee

Life Science Reit PLC Announces Executive Changes

Recent updates

Price target decreased by 16% to UK£0.51

First half dividend of UK£0.01 announced

First half 2024 earnings released: UK£0.037 loss per share (vs UK£0.015 profit in 1H 2023)

Life Science REIT plc to Report First Half, 2024 Results on Sep 26, 2024

Price target decreased by 20% to UK£0.68

Full year 2023 earnings: EPS and revenues miss analyst expectations

Life Science REIT plc, Annual General Meeting, May 23, 2024

High number of new and inexperienced directors

Life Science REIT plc to Report Fiscal Year 2023 Results on Mar 26, 2024

First half 2023 earnings released

Life Science REIT plc Declares an Interim Dividend for the Six Months Ended 30 June 2023, Payable on 31 October 2023

Life Science REIT plc to Report Q2, 2023 Results on Sep 21, 2023

Upcoming dividend of UK£0.03 per share at 6.6% yield

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Life Science REIT plc Declares First Interim Dividend, Payable on 31 October 2022

Life Science REIT plc Approves Election of Directors

Life Science Reit plc Announces Change of Role of Richard Howell from Non-Executive Director to Senior Independent Director and Appointment as Chair of the Audit and Risk Committee

Life Science Reit PLC to Report First Half, 2022 Results on Sep 22, 2022

Life Science Reit PLC (AIM:LABS) acquired Oxford Technology Park from Angus and Alicia Bates for £120.3 Million.

Life Science Reit PLC (AIM:LABS) acquired 7-11 Herbrand Street from LabTech Investments Ltd for £85 million.

Life Science Reit PLC Announces Executive Changes

Life Science Reit PLC (AIM:LABS) acquired three freehold buildings at Cambourne Business Park near Cambridge from Coal Pension Properties Limited for £50.1 million.

Life Science Reit PLC (AIM:LABS) acquired Three buildings at the Cambourne Business Park near Cambridge for £38.7 million.

Life Science Reit PLC (AIM:LABS) acquired The Merrifield Centre in Cambridge for £4.8 million.

Life Science Reit PLC (AIM:LABS) acquired Rolling Stock Yard from Newmark Property Investments Ltd., Investec Bank Limited (JSE:INLP) and Argo Real Estate Management Limited for £77 million.

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd